Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Vir Biotechnology, Inc. (VIR)
A forensic read on Vir Biotechnology, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-1.0
Altman Z-score
Clean
Earnings quality
3
Forensic signals
-49.3%
ROE
$1.7B
Market cap
Vir Biotechnology, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -1.0, placing it in the Distress zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-56%Return on invested capital.Return on invested capital is -56% and slipping from 39% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+0.9%/yrShare-count dilution.Diluted share count changed +3% over the last 3 years to FY2025 (+0.9%/yr). Roughly flat — buybacks are about offsetting stock comp, not shrinking the count. Per-share value isn't being meaningfully helped or hurt by the count.
72% of revStock-based comp load.Stock-based compensation ran 72% of revenue in FY2025 — about $0.35 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-638.9%
Free Cash Flow$-396.6M
Latest Revenue$68.6M
Return on Equity-57.2%
Revenue Growth YoY-7.6%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Vir Biotechnology, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about VIR's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown